Items Tagged ‘cabozantinib’

February 20, 2018

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer

By

CancerConnect News:  Treatment with Cabometyx  (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population.  The new findings come from the phase 3 CELESTIAL trial and were presented at the 2018 Gastrointestinal Cancers Symposium.1 About Liver Cancer Liver […]

View full entry

Tags: Cabometyx, cabozantinib, hepatocellular cancer, Liver Cancer, News


January 5, 2018

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma

By

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.  The FDA previously approved Cabometyx in 2016 for treatment of […]

View full entry

Tags: Cabometyx, cabozantinib, kidney cancer, News, Renal Cancer, renal cell carcinoma, Sutent